Extemporaneous Formulations for Pediatric Patients: Global Necessities, Challenges and Opportunities

Many commercially available medications are often unapproved or unavailable in suitable dosage forms for specific patient populations, particularly infants and children. This necessitates the use of extemporaneously compounded formulations to deliver individualized doses based on body weight or body surface area, and when a medication is unavailable at an appropriate concentration or contains excipients potentially unsafe for certain patients. Extemporaneous compounding is required for oral liquids when patients are unable to swallow tablets or capsules. It is also needed for topical preparations and sterile dosage forms when commercial products are unavailable. Across regions, practices follow national pharmacopeial standards for both sterile and non-sterile compounding. Stability factors influencing the safety and efficacy of compounded formulations must be carefully considered when assigning appropriate beyond-use dates. While stability information is available for some medications in monographs, peer-reviewed literature, prescribing information, and investigator's brochures, such data is often lacking for many compounded preparations. Emerging extemporaneous formulations-such as orodispersible films, nanoparticle systems, and 3D-printed compounds-offer potential advantages over traditional compounded formulations but present unique challenges to widespread implementation. Despite the justified clinical need for extemporaneous compounding, significant barriers remain, including limited access to medications, insufficient compounding expertise or resources, gaps in pharmacokinetic and safety data, and regulatory constraints. This review critically appraises the current state of extemporaneous compounding-drawing primarily on the United States of America frameworks-and highlights its continued necessity, associated challenges, and pragmatic solutions for advancing personalized pharmacotherapy across pediatric age groups worldwide.

Authors

Institutions

Publication Details

Journal
Pharmaceutics
Published
2026-01-19
DOI
https://doi.org/10.3390/pharmaceutics18010126
Citations
1
Primary Topic
Pharmaceutical studies and practices
Type
article
Field-Weighted Citation Impact
41.22
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Extemporaneous Formulations for Pediatric Patients: Global Necessities, Challenges and Opportunities

Milap Chand Nahata, Vinita Balakrishna Pai
1 citations
Pharmaceutics
Pharmaceutical studies and practices
41.22
article

Extemporaneous Formulations for Pediatric Patients: Global Necessities, Challenges and Opportunities

Milap Chand Nahata, Vinita Balakrishna Pai
article en
1 citations

Abstract

Many commercially available medications are often unapproved or unavailable in suitable dosage forms for specific patient populations, particularly infants and children. This necessitates the use of extemporaneously compounded formulations to deliver individualized doses based on body weight or body surface area, and when a medication is unavailable at an appropriate concentration or contains excipients potentially unsafe for certain patients. Extemporaneous compounding is required for oral liquids when patients are unable to swallow tablets or capsules. It is also needed for topical preparations and sterile dosage forms when commercial products are unavailable. Across regions, practices follow national pharmacopeial standards for both sterile and non-sterile compounding. Stability factors influencing the safety and efficacy of compounded formulations must be carefully considered when assigning appropriate beyond-use dates. While stability information is available for some medications in monographs, peer-reviewed literature, prescribing information, and investigator's brochures, such data is often lacking for many compounded preparations. Emerging extemporaneous formulations-such as orodispersible films, nanoparticle systems, and 3D-printed compounds-offer potential advantages over traditional compounded formulations but present unique challenges to widespread implementation. Despite the justified clinical need for extemporaneous compounding, significant barriers remain, including limited access to medications, insufficient compounding expertise or resources, gaps in pharmacokinetic and safety data, and regulatory constraints. This review critically appraises the current state of extemporaneous compounding-drawing primarily on the United States of America frameworks-and highlights its continued necessity, associated challenges, and pragmatic solutions for advancing personalized pharmacotherapy across pediatric age groups worldwide.

PharmaceuticsVol. 18(1)
The Ohio State University (US)
Partnerships for the goals
Openalex Percentile: Top 1%
Pharmaceutical studies and practices
41.22
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Extemporaneous Formulations for Pediatric Patients: Global Necessities, Challenges and Opportunities — Milap Chand Nahata, Vinita Balakrishna Pai · Pharmaceutics (2026) | TGRS Research Map | TGRS